UCBJY Overview
Upcoming Projects (UCBJY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (UCBJY)
-
A Second Look: Reviewing the data presented at ACR 2024 from the Phase 3 PHOENYCS GO clinical trial of Dapirolizumab pegol (DZP) in patients with SLE
Tickers: UCBJY, BIIB
Executed On: Nov 21, 2024 at 01:30 PM EST -
Reviewing the data presented at ACR 2024 from the Phase 3 PHOENYCS GO clinical trial of Dapirolizumab pegol (DZP) in patients with SLE
Tickers: UCBJY, BIIB
Executed On: Nov 21, 2024 at 09:00 AM EST -
Discussing the recent approval of BIMZELX (bimekizumab-bkzx) as a treatment for psoriatic arthritis, nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Ticker: UCBJY
Executed On: Oct 09, 2024 at 10:00 AM EDT -
A Third View: Discussing the two-year data from the phase 3 BE MOBILE 1 and BE MOBILE 2 clinical trials of BIMZELX arthritis presented at EULAR 2024
Ticker: UCBJY
Executed On: Oct 03, 2024 at 02:00 PM EDT -
A third look: Delving into the recent data released on CIMZIA in women living with chronic rheumatic diseases throughout pregnancy and post-partum.
Ticker: UCBJY
Executed On: Sep 06, 2024 at 02:00 PM EDT -
A second look:Delving into the recent data released on CIMZIA in women living with chronic rheumatic diseases throughout pregnancy and post-partum.
Ticker: UCBJY
Executed On: Aug 14, 2024 at 10:00 AM EDT -
Delving into the recent data released on CIMZIA in women living with chronic rheumatic diseases throughout pregnancy and post-partum.
Ticker: UCBJY
Executed On: Aug 13, 2024 at 05:00 PM EDT -
A Second View: Discussing the two-year data from the phase 3 BE MOBILE 1 and BE MOBILE 2 clinical trials of BIMZELX arthritis presented at EULAR 2024
Ticker: UCBJY
Executed On: Jul 15, 2024 at 06:15 PM EDT -
Discussing the two-year data from the phase 3 BE MOBILE 1 and BE MOBILE 2 clinical trials of BIMZELX arthritis presented at EULAR 2024
Ticker: UCBJY
Executed On: Jul 11, 2024 at 03:45 PM EDT -
Discussing the recent FDA Approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis as a result of the data from the pivotal Phase 3 MycarinG study.
Ticker: UCBJY
Executed On: Aug 02, 2023 at 05:00 PM EDT -
A Second View: Discussing the potential use of UCB's Bimekizumab in treating hidradenitis suppurativa
Ticker: UCBJY
Executed On: Apr 10, 2023 at 03:30 PM EDT -
Discussing the potential use of UCB's Bimekizumab in treating hidradenitis suppurativa
Ticker: UCBJY
Executed On: Mar 29, 2023 at 09:00 AM EDT
Upcoming & Overdue Catalysts (UCBJY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (UCBJY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
